Matches in DBpedia 2015-10 for { ?s ?p "Zerona is a low-level laser device developed by Erchonia Corp. for non-invasive body slimming of the waist, hips, and thighs. It has been shown to disrupt adipocyte, or fat cell, membranes causing the release of stored lipids and fatty material, in turn, promoting adipocyte collapse. The device was first introduced to the market in 2008 as an off-label use device for slimming, but later was cleared as a Class II medical device by the Food and Drug Administration in 2010 indicated for use as a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist, and thighs. Zerona was the first aesthetic device to receive this indication by the FDA following the completion of a placebo-controlled, randomized, double-blind, multi-centered clinical trial. Clinical study participants randomly assigned to receive “active” or real treatment displayed an average loss of 3.5 in (8.9 cm) across the waist, hips, and thighs in two weeks. This was compared to study participants randomly assigned to the “sham” or placebo group who exhibited a reduction of 0.68 in (1.7 cm) after two weeks."@en }
Showing triples 1 to 1 of
1
with 100 triples per page.
- Zerona abstract "Zerona is a low-level laser device developed by Erchonia Corp. for non-invasive body slimming of the waist, hips, and thighs. It has been shown to disrupt adipocyte, or fat cell, membranes causing the release of stored lipids and fatty material, in turn, promoting adipocyte collapse. The device was first introduced to the market in 2008 as an off-label use device for slimming, but later was cleared as a Class II medical device by the Food and Drug Administration in 2010 indicated for use as a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist, and thighs. Zerona was the first aesthetic device to receive this indication by the FDA following the completion of a placebo-controlled, randomized, double-blind, multi-centered clinical trial. Clinical study participants randomly assigned to receive “active” or real treatment displayed an average loss of 3.5 in (8.9 cm) across the waist, hips, and thighs in two weeks. This was compared to study participants randomly assigned to the “sham” or placebo group who exhibited a reduction of 0.68 in (1.7 cm) after two weeks.".